Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Molecular Templates
company
About
Molecular Templates develops novel therapeutic compounds for cancer.
- 251 - 500
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $60M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2000
- Number Of Employee
- 251 - 500
- Operating Status
- Active
Molecular Templates is a biopharmaceutical company with a novel protein platform for the development of new therapeutics against cancer. The company has a lead compound for melanoma that is expected to enter into clinical trials in the next two years and is developing additional compounds against a variety of other cancers.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$60.15M
Molecular Templates has raised a total of
$60.15M
in funding over 2 rounds. Their latest funding was raised on
Aug 16, 2017 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 16, 2017 | Post-IPO Equity | $60M | 1 | — | — | Detail |
| Jan 1, 2010 | Grant | $153.93K | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Molecular Templates is funded by 2 investors.
Takeda
and National Institutes of Health
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Takeda
|
— | Post-IPO Equity |
National Institutes of Health
|
— | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
